Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Young L, Dong O, Wiltshire T, Kypzyk K, Guenzel N. MC4R polymorphism associated with antipsychotic-associated weight gain. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 17, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:121. doi: 10.1159/000480052
Dong OM, Suzuki O, Howard R, Jamieson K, Pointer M, Kohlmeier T, Wiltshire T. Using targeted next-generation sequencing as a cost-efficient method to characterize the genetics of salt sensitivity. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 18, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:100. doi: 10.1159/000480052
Bartha E, Davidson T, Brodtkorb T, Carlsson P, Kalman S. Value of information: interim analysis of a randomized, controlled trial of goal-directed hemodynamic treatment for aged patients. Trials. 2013 Jul 9;14:205.
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X